Dr. Alan R. Saltiel studies the molecular and cellular biology of insulin growth and action. He has directed drug discovery activities in diabetes, obesity, and cancer, having led preclinical studies on the first thiazolidinedione approved for the treatment of type 2 diabetes, troglitazone. He also developed the first MEK inhibitors for the treatment of cancer, which received the U.S. Food and Drug Administration approval for melanoma and other cancers. He has given many named lectures and organized numerous meetings and conferences, and served on a number of advisory panels, scientific and editorial boards. He has 19 issued patents and has published over 290 original papers.
